The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.
NOTE: This Case Evaluation form can also be completed for situations that involve other incretin mimetic drugs which are used as diabetes medications, such as Bydureon, Januvia, and Victoza -- even in there is no Byetta involved.
Diabetes drugs in the incretin mimetic class -- and their manufacturers -- include:
Exenatide (Byetta, Bydureon / injection) -- Amylin, which was acquired by Bristol Myers Squibb (BMS), which co-markets with Astra-Zeneca (AZ);
Liraglutide (Victoza / injection) -- Novo Nordisk;
Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync / tablets) -- Merck;
Saxagliptin (Onglyza, Kombiglyze XR / tablets) -- BMS/AZ;
Alogliptin (Nesina, Kazano, Oseni / tablets) -- Takeda; and,
Linagliptin (Tradjenta, Jentadueto / tablets) -- Boehringer Ingelheim
My Articles About Byetta
Health Canada Currently Conducting Epidemiological Study Of These Incretin-Based Type 2 Diabetes Medications To Assess This Potential Drug Safety Issue
SUMMARY: Among the diabetes medications that fall into the incretin-based therapies class of drugs are:
- Bydureon (exenatide)
- Byetta (exenatide)
- Januvia (sitagliptin)
- Victoza (liraglutide)
We have written previously about the possible link between these diabetes drugs and cancer of the pancreas / pancreatic cancer.
From this article in the October 2014 edition of the Canadian Adverse Reaction Newsletter, “Incretin-based therapies and the risk of pancreatic cancer”, we learned that there is an epidemiological study being done by Health Canada to assess the potential association between pancreatic cancer and incretin-based diabetes drugs such as Bydureon, Byetta, Januvia, and Victoza.
Earlier Byetta articles by Tom Lamb on the Drug Injury Watch blog:
Drug Injury Watch: Warnings About Byetta Associated With Risk Of Severe Pancreatitis And Renal Failure
Drug Injury Watch: August 2008: Byetta Associated With Hemorrhagic Pancreatitis And Necrotizing Pancreatitis